Business Description
Veru Inc
NAICS : 541713
SIC : 2834
ISIN : US92536C1036
Description
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.13 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.91 | |||||
| Beneish M-Score | -4.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -33 | |||||
| 3-Year EBITDA Growth Rate | -67.6 | |||||
| 3-Year EPS without NRI Growth Rate | -151.5 | |||||
| 3-Year FCF Growth Rate | -222.9 | |||||
| 3-Year Book Growth Rate | -20.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.81 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -13.64 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.9 | |||||
| 9-Day RSI | 59.14 | |||||
| 14-Day RSI | 53.91 | |||||
| 3-1 Month Momentum % | -16.76 | |||||
| 6-1 Month Momentum % | -22.26 | |||||
| 12-1 Month Momentum % | -16.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.62 | |||||
| Quick Ratio | 3.16 | |||||
| Cash Ratio | 2.74 | |||||
| Days Inventory | 232.15 | |||||
| Days Sales Outstanding | 84.96 | |||||
| Days Payable | 365.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.5 | |||||
| Shareholder Yield % | -30.82 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.4 | |||||
| Operating Margin % | -276.15 | |||||
| Net Margin % | -265.42 | |||||
| FCF Margin % | -191.75 | |||||
| ROE % | -99.21 | |||||
| ROA % | -54.65 | |||||
| ROIC % | -122.37 | |||||
| 3-Year ROIIC % | 2195.19 | |||||
| ROC (Joel Greenblatt) % | -562.18 | |||||
| ROCE % | -69.12 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.17 | |||||
| PB Ratio | 2.86 | |||||
| Price-to-Tangible-Book | 3.5 | |||||
| EV-to-EBIT | -2.56 | |||||
| EV-to-EBITDA | -2.58 | |||||
| EV-to-Revenue | 6.53 | |||||
| EV-to-Forward-Revenue | 6.43 | |||||
| EV-to-FCF | -3.41 | |||||
| Price-to-GF-Value | 1.08 | |||||
| Price-to-Median-PS-Value | 1.34 | |||||
| Price-to-Net-Current-Asset-Value | 9.18 | |||||
| Price-to-Net-Cash | 73.46 | |||||
| Earnings Yield (Greenblatt) % | -39.06 | |||||
| FCF Yield % | -25.13 | |||||
| Forward Rate of Return (Yacktman) % | 0.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VERU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Veru Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.092 | ||
| EPS (TTM) ($) | -0.3 | ||
| Beta | -1.86 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 116.03 | ||
| 14-Day RSI | 53.91 | ||
| 14-Day ATR ($) | 0.054548 | ||
| 20-Day SMA ($) | 0.683875 | ||
| 12-1 Month Momentum % | -16.26 | ||
| 52-Week Range ($) | 0.36 - 1.92 | ||
| Shares Outstanding (Mil) | 146.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veru Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veru Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Veru Inc Frequently Asked Questions
What is Veru Inc(VERU)'s stock price today?
The current price of VERU is $0.73. The 52 week high of VERU is $1.92 and 52 week low is $0.36.
When is next earnings date of Veru Inc(VERU)?
The next earnings date of Veru Inc(VERU) is 2025-02-07 Est..
Does Veru Inc(VERU) pay dividends? If so, how much?
Veru Inc(VERU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers